Daniel Steven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Steven has a total of 658 co-authors. Here are the top co-authors by number of shared publications:
- Arian Sultan
Department of Cardiology, Asklepios Klinik St. Georg , Hamburg
30 shared publications - Jakob Lüker
Abteilung für Elektrophysiologie, Universität zu Köln, Herzzentrum der Uniklinik Köln, Köln, Deutschland
23 shared publications - Jan-Hendrik van Den Bruck
Department for Electrophysiology, Heart Center University Hospital of Cologne, 50937 Cologne, Germany
23 shared publications - Jan-Hendrik Schipper
Department for Electrophysiology, Heart Center University Hospital of Cologne, 50937 Cologne, Germany
16 shared publications - Cornelia Scheurlen
Department for Electrophysiology, Heart Center University Hospital of Cologne, 50937 Cologne, Germany
15 shared publications - Philipp Sommer
Clinic for Electrophysiology, Herz- und Diabeteszentrum NRW, Ruhr-University Bochum , Bad Oeynhausen
14 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Springer Nature in Herzschrittmachertherapie + Elektrophysiologie
- Vol. 37 (2) , 229-238
DGK Positionspapier – Qualitätssicherung zur Durchführung der Katheterablation von Vorhofflimmern: Executive Summary
Zusammenfassung: Das aktualisierte Positionspapier der DGK zur Katheterablation von Vorhofflimmern (AF) [1] stellt die aktuelle Evidenz, Techniken und Qualitätsstandards dar, die sich seit 2017 gemeinsam mit Indikation, Technik und Rolle der Ablation in der Therapie deutlich gewandelt haben. Die Pulmonalvenenisolation (PVI) bleibt zentraler Bestandteil der AF-Ablation. Neben etablierten Verfahren wie Radiofrequenz- und Kryoablation gewinnt die Pulsed-Field-Ablation (PFA) an Bedeutung. Bei persistierendem AF fehlen klare Empfehlungen über die PVI hinaus, trotz zunehmender Daten für ergänzende Ablationsstrategien. Die Versorgungssituation zeigt eine starke Zunahme der Ablationen, wobei die tagesgleiche Entlassung nur für selektierte Patienten empfohlen wird. Die präzise Patientenselektion, inklusive Anamnese, Risikofaktoren und Bildgebung sind entscheidend für den Erfolg und die Sicherheit. Die Bedeutung von periprozeduralem Management und strukturierter Nachsorge wird hervorgehoben. Komplikationen wie Perikardtamponade, Schlaganfall und Phrenikusparese erfordern strukturierte Abläufe und erfahrene Teams. Besonders bei Patienten mit Herzinsuffizienz zeigt sich die Ablation als potenziell prognoseverbessernd. Die Zertifizierung von Zentren durch die DGK dient der Qualitätssicherung. Neue Entwicklungen wie KI-gestützte Ablationsplanung und Studien zur OAK-Strategie nach Ablation werden die Praxis weiter verändern.
- 19 May 2026
- Published by Springer Nature in Herzschrittmachertherapie + Elektrophysiologie
- Vol. 37 (2) , 229-238
Open AccessDGK Positionspapier – Qualitätssicherung zur Durchführung der Katheterablation von Vorhofflimmern: Executive Summary
Zusammenfassung: Das aktualisierte Positionspapier der DGK zur Katheterablation von Vorhofflimmern (AF) [1] stellt die aktuelle Evidenz, Techniken und Qualitätsstandards dar, die sich seit 2017 gemeinsam mit Indikation, Technik und Rolle der Ablation in der Therapie deutlich gewandelt haben. Die Pulmonalvenenisolation (PVI) bleibt zentraler Bestandteil der AF-Ablation. Neben etablierten Verfahren wie Radiofrequenz- und Kryoablation gewinnt die Pulsed-Field-Ablation (PFA) an Bedeutung. Bei persistierendem AF fehlen klare Empfehlungen über die PVI hinaus, trotz zunehmender Daten für ergänzende Ablationsstrategien. Die Versorgungssituation zeigt eine starke Zunahme der Ablationen, wobei die tagesgleiche Entlassung nur für selektierte Patienten empfohlen wird. Die präzise Patientenselektion, inklusive Anamnese, Risikofaktoren und Bildgebung sind entscheidend für den Erfolg und die Sicherheit. Die Bedeutung von periprozeduralem Management und strukturierter Nachsorge wird hervorgehoben. Komplikationen wie Perikardtamponade, Schlaganfall und Phrenikusparese erfordern strukturierte Abläufe und erfahrene Teams. Besonders bei Patienten mit Herzinsuffizienz zeigt sich die Ablation als potenziell prognoseverbessernd. Die Zertifizierung von Zentren durch die DGK dient der Qualitätssicherung. Neue Entwicklungen wie KI-gestützte Ablationsplanung und Studien zur OAK-Strategie nach Ablation werden die Praxis weiter verändern.
- Open Access
- 16 April 2026
- Published by Springer Nature in Clinical Research in Cardiology
Hospitalization profiles and complications across ICD and CRT-D implantations in Germany: data from the VIDEO study
Background: Implantable cardioverter-defibrillator (ICD) is a cornerstone therapy for the prevention of sudden cardiac death. However, clinical profiles and in-hospital outcomes may differ according to device type—single-chamber ICD, dual-chamber ICD, or cardiac resynchronization therapy defibrillator (CRT-D). This study aimed to compare hospitalization parameters and peri-procedural complications among patients receiving these device types. Methods: We retrospectively analyzed 2,001 consecutive ICD recipients (single-chamber: 815; dual-chamber: 463; CRT-D: 723). Baseline characteristics, intensive care unit (ICU) utilization, procedure-related complications, and discharge outcomes were compared across groups. The main endpoint was defined as major adverse cardiovascular and cerebrovascular events (MACCE), and the second endpoint was defined as an extended MACCE including both MACCE and intensive care unit (ICU) admission. Results: CRT-D recipients were older (67.5 ± 10.4 years, p < 0.01) and had a higher prevalence of comorbidities, including obesity (12.3%, p = 0.03), diabetes mellitus (30.2%, p = 0.04), permanent atrial fibrillation (10.1%, p < 0.01), and chronic kidney disease (31%, p < 0.01), compared with single- and dual-chamber ICD patients. Post-procedural ICU admission was highest in the dual-chamber ICD group (44.5%, p < 0.01), while ICU stay was shortest among CRT-D recipients (median 2.9 days, p < 0.01), who also required mechanical ventilation less frequently (8.7%, p < 0.01). Overall complication rates were lowest in the single-chamber ICD group (7.5%). Compared with single-chamber ICDs, implantation of dual-chamber ICDs was associated with a significantly higher risk of extended MACCE [OR:1.65, (95% CI:1.30–2.09)], whereas CRT-Ds were associated with a significantly lower risk [OR:0.75, (95% CI:0.60–0.94)]. Furthermore, CRT-Ds were associated with a substantially lower extended MACCE risk compared with dual-chamber ICDs [OR: 0.45, (95% CI:0.35–0x”.58)]. Defibrillator type and age emerged as significant predictors of MACCE. For the extended MACCE endpoint, defibrillator type remained a significant predictor, whereas age was not. Conclusion: Despite their older age and higher comorbidity burden, recipients of CRT-D exhibited the lowest incidence of MACCE. Defibrillator type and age were identified as relevant predictors of MACCE in this patient population. Graphical
- 16 April 2026
- Published by Springer Nature in Clinical Research in Cardiology
Open AccessHospitalization profiles and complications across ICD and CRT-D implantations in Germany: data from the VIDEO study
Background: Implantable cardioverter-defibrillator (ICD) is a cornerstone therapy for the prevention of sudden cardiac death. However, clinical profiles and in-hospital outcomes may differ according to device type—single-chamber ICD, dual-chamber ICD, or cardiac resynchronization therapy defibrillator (CRT-D). This study aimed to compare hospitalization parameters and peri-procedural complications among patients receiving these device types. Methods: We retrospectively analyzed 2,001 consecutive ICD recipients (single-chamber: 815; dual-chamber: 463; CRT-D: 723). Baseline characteristics, intensive care unit (ICU) utilization, procedure-related complications, and discharge outcomes were compared across groups. The main endpoint was defined as major adverse cardiovascular and cerebrovascular events (MACCE), and the second endpoint was defined as an extended MACCE including both MACCE and intensive care unit (ICU) admission. Results: CRT-D recipients were older (67.5 ± 10.4 years, p < 0.01) and had a higher prevalence of comorbidities, including obesity (12.3%, p = 0.03), diabetes mellitus (30.2%, p = 0.04), permanent atrial fibrillation (10.1%, p < 0.01), and chronic kidney disease (31%, p < 0.01), compared with single- and dual-chamber ICD patients. Post-procedural ICU admission was highest in the dual-chamber ICD group (44.5%, p < 0.01), while ICU stay was shortest among CRT-D recipients (median 2.9 days, p < 0.01), who also required mechanical ventilation less frequently (8.7%, p < 0.01). Overall complication rates were lowest in the single-chamber ICD group (7.5%). Compared with single-chamber ICDs, implantation of dual-chamber ICDs was associated with a significantly higher risk of extended MACCE [OR:1.65, (95% CI:1.30–2.09)], whereas CRT-Ds were associated with a significantly lower risk [OR:0.75, (95% CI:0.60–0.94)]. Furthermore, CRT-Ds were associated with a substantially lower extended MACCE risk compared with dual-chamber ICDs [OR: 0.45, (95% CI:0.35–0x”.58)]. Defibrillator type and age emerged as significant predictors of MACCE. For the extended MACCE endpoint, defibrillator type remained a significant predictor, whereas age was not. Conclusion: Despite their older age and higher comorbidity burden, recipients of CRT-D exhibited the lowest incidence of MACCE. Defibrillator type and age were identified as relevant predictors of MACCE in this patient population. Graphical
- Open Access
- 16 April 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (36) , 5128-5138
Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trial
Background and Aims: Patients with heart failure with reduced ejection fraction (HFrEF) derive less benefit from cardiac resynchronization therapy (CRT) if they have coexisting atrial fibrillation (AF). Observational data suggest that atrioventricular node ablation (AVNA) may enhance CRT efficacy in this population. This trial aimed to evaluate the effect of AVNA compared with medical rate control therapy (MRCT) on CRT outcomes in patients with HFrEF and permanent AF. Methods: The CAAN-AF trial was an international, prospective, multicentre, randomized controlled trial evaluating the impact of AVNA in patients with HFrEF, permanent AF, and CRT-defibrillators (CRT-D). Participants were randomly assigned (1:1) to AVNA or MRCT targeting a resting heart rate <90 bpm. All participants received device optimization. The primary endpoint was a composite of all-cause mortality and nonfatal heart failure events. Secondary endpoints included cardiovascular mortality, unplanned hospitalizations, ventricular arrhythmias requiring device therapy, 6-min walk distance (6MWD), and quality of life. Results: With early termination of the trial due to futility, a total of 143 patients were randomized (67 to AVNA, 76 to MRCT). Baseline characteristics were similar across groups. No significant difference was found in the primary endpoint [47 vs. 46 events; incident rate ratio (IRR), 1.16; 95% confidence interval (CI), 0.60–2.24]. Secondary outcomes, including cardiovascular mortality (odds ratio, 1.93; 95% CI 0.60–6.20), unplanned hospitalizations (IRR, 1.01; 95% CI 0.71–1.74), ventricular arrhythmias requiring device therapy (IRR, 0.68; 95% CI 0.17–2.63), 6MWD, and SF-36 scores, also showed no significant differences. Conclusions: This randomized trial of patients with permanent AF and CRT-D found no evidence of a reduction in all-cause mortality and nonfatal heart failure events with AVNA compared with MRCT. Trial Registration: NCT01522898.
- 16 April 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (36) , 5128-5138
Open AccessCardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trial
Background and Aims: Patients with heart failure with reduced ejection fraction (HFrEF) derive less benefit from cardiac resynchronization therapy (CRT) if they have coexisting atrial fibrillation (AF). Observational data suggest that atrioventricular node ablation (AVNA) may enhance CRT efficacy in this population. This trial aimed to evaluate the effect of AVNA compared with medical rate control therapy (MRCT) on CRT outcomes in patients with HFrEF and permanent AF. Methods: The CAAN-AF trial was an international, prospective, multicentre, randomized controlled trial evaluating the impact of AVNA in patients with HFrEF, permanent AF, and CRT-defibrillators (CRT-D). Participants were randomly assigned (1:1) to AVNA or MRCT targeting a resting heart rate <90 bpm. All participants received device optimization. The primary endpoint was a composite of all-cause mortality and nonfatal heart failure events. Secondary endpoints included cardiovascular mortality, unplanned hospitalizations, ventricular arrhythmias requiring device therapy, 6-min walk distance (6MWD), and quality of life. Results: With early termination of the trial due to futility, a total of 143 patients were randomized (67 to AVNA, 76 to MRCT). Baseline characteristics were similar across groups. No significant difference was found in the primary endpoint [47 vs. 46 events; incident rate ratio (IRR), 1.16; 95% confidence interval (CI), 0.60–2.24]. Secondary outcomes, including cardiovascular mortality (odds ratio, 1.93; 95% CI 0.60–6.20), unplanned hospitalizations (IRR, 1.01; 95% CI 0.71–1.74), ventricular arrhythmias requiring device therapy (IRR, 0.68; 95% CI 0.17–2.63), 6MWD, and SF-36 scores, also showed no significant differences. Conclusions: This randomized trial of patients with permanent AF and CRT-D found no evidence of a reduction in all-cause mortality and nonfatal heart failure events with AVNA compared with MRCT. Trial Registration: NCT01522898.
- Open Access
- 1 December 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (12)
Transforming atrial fibrillation management by targeting comorbidities and reducing atrial fibrillation burden: the 10th AFNET/EHRA consensus conference
Atrial fibrillation (AF) is a growing unmet medical need. To reduce its impact on patients’ lives, improvements in stroke prevention therapy, treatment of concomitant conditions, and rhythm control therapy are actively developed: Innovations in anti-thrombotic agents, new anti-arrhythmic drugs (AADs), and novel interventional rhythm control therapies emerge alongside AF-reducing effects of general cardiometabolic therapies. Simple risk scores are slowly replaced by personalized AF risk estimation using quantifiable features. These developments were discussed by over 80 experts from academia and industry during the 10th Atrial Fibrillation NETwork /European Heart Rhythm Association consensus conference from 5 to 7 May 2025. The emerging consensus, described here, is multi-domain therapy combining stroke prevention, rhythm control, and therapy of concomitant cardiovascular conditions. This combines anti-coagulants, AADs, and AF ablation with old and new cardiometabolic drugs that can reduce AF risk, AF burden, and AF-related complications at scale. The paper furthermore describes quantitative traits that may enable a shift towards risk-driven therapy based on AF phenotypes. These can enable adjusted therapy strategies that are safe, accessible, and patient-centred. Applying modern data science and artificial intelligence methods to quantitative phenotypic and genetic features can further improve risk estimation and personalized therapy selection. At the same time, translational and clinical research into reversing the drivers of AF and into improved stroke prevention through new drugs and through combination therapies is needed. Together, these efforts offer pathways towards personalized, patient-centred, multi-modal, and accessible AF management that integrates rhythm control, stroke prevention, and therapy of concomitant conditions to bridge today’s practical needs with tomorrow’s therapeutic innovation.
- 1 December 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (12)
Open AccessTransforming atrial fibrillation management by targeting comorbidities and reducing atrial fibrillation burden: the 10th AFNET/EHRA consensus conference
Atrial fibrillation (AF) is a growing unmet medical need. To reduce its impact on patients’ lives, improvements in stroke prevention therapy, treatment of concomitant conditions, and rhythm control therapy are actively developed: Innovations in anti-thrombotic agents, new anti-arrhythmic drugs (AADs), and novel interventional rhythm control therapies emerge alongside AF-reducing effects of general cardiometabolic therapies. Simple risk scores are slowly replaced by personalized AF risk estimation using quantifiable features. These developments were discussed by over 80 experts from academia and industry during the 10th Atrial Fibrillation NETwork /European Heart Rhythm Association consensus conference from 5 to 7 May 2025. The emerging consensus, described here, is multi-domain therapy combining stroke prevention, rhythm control, and therapy of concomitant cardiovascular conditions. This combines anti-coagulants, AADs, and AF ablation with old and new cardiometabolic drugs that can reduce AF risk, AF burden, and AF-related complications at scale. The paper furthermore describes quantitative traits that may enable a shift towards risk-driven therapy based on AF phenotypes. These can enable adjusted therapy strategies that are safe, accessible, and patient-centred. Applying modern data science and artificial intelligence methods to quantitative phenotypic and genetic features can further improve risk estimation and personalized therapy selection. At the same time, translational and clinical research into reversing the drivers of AF and into improved stroke prevention through new drugs and through combination therapies is needed. Together, these efforts offer pathways towards personalized, patient-centred, multi-modal, and accessible AF management that integrates rhythm control, stroke prevention, and therapy of concomitant conditions to bridge today’s practical needs with tomorrow’s therapeutic innovation.
- 10 November 2025
- Published by Springer Nature in Die Kardiologie
- Vol. 19 (6) , 440-454
Qualitätskriterien zur Durchführung der Katheterablation von Vorhofflimmern – DGK-Positionspapier
- 10 November 2025
- Published by Springer Nature in Die Kardiologie
- Vol. 19 (6) , 440-454
Qualitätskriterien zur Durchführung der Katheterablation von Vorhofflimmern – DGK-Positionspapier
- Open Access
- 7 October 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (10)
Influence of proton pump inhibitors on the incidence and clinical course of oesophageal fistula following catheter ablation for atrial fibrillation: a subanalysis of the POTTER-AF study
- 7 October 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (10)
Open AccessInfluence of proton pump inhibitors on the incidence and clinical course of oesophageal fistula following catheter ablation for atrial fibrillation: a subanalysis of the POTTER-AF study
- Open Access
- 16 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5801
Preprocedural Substrate Visualization and Image Integration Based on Late Enhancement Computed Tomography for Ventricular Tachycardia Ablation in Non-Ischemic Cardiomyopathy
Background/Objectives: Catheter ablation is an established therapy for ventricular tachycardia (VT), though outcomes remain limited in patients with non-ischemic dilated cardiomyopathy (NIDCM) due to complex arrhythmogenic substrates. Late iodine enhancement computed tomography (LIE-CT) offers a promising alternative to cardiac MRI for preprocedural substrate visualization. This study evaluated procedural characteristics and outcomes of LIE-CT-supported VT ablation versus conventional mapping (CM) in NIDCM patients. Methods: NIDCM patients undergoing VT ablation between January 2022 and August 2024 were retrospectively analyzed. LIE-CT data were processed using inHEART software. Patients were matched 1:1 by propensity score based on baseline characteristics, electrical storm, and prior ablations. Results: A total of 46 patients (mean age 59 ± 16.4 years, 74% male) were included (23 LIE-CT, 23 CM). Procedure durations were comparable (231.5 ± 74.2 vs. 220.2 ± 70.2 min, p = 0.5), but mapping time (35.9 ± 15.3 vs. 54 ± 5 min, p < 0.001) and fluoroscopy time (14.7 ± 5.1 vs. 21.3 ± 10.6 min, p = 0.02) were significantly shorter with LIE-CT. Epicardial access was more frequent (52% vs. 26%, p < 0.001), and bipolar ablation for intramural scar was performed in 17% of LIE-CT cases. There were no significant differences in acute kidney injury or 30-day mortality. At a median follow-up of 367 days, VT-free survival was 57% with LIE-CT and 52% with CM (p = 0.8). Conclusions: LIE-CT-supported VT ablation and substrate visualization was safe, without additional risk of acute kidney injury, and enabled more efficient and targeted VT ablation. Prospective studies are warranted to assess its impact on long-term outcomes in NIDCM patients.
- 16 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5801
Open AccessPreprocedural Substrate Visualization and Image Integration Based on Late Enhancement Computed Tomography for Ventricular Tachycardia Ablation in Non-Ischemic Cardiomyopathy
Background/Objectives: Catheter ablation is an established therapy for ventricular tachycardia (VT), though outcomes remain limited in patients with non-ischemic dilated cardiomyopathy (NIDCM) due to complex arrhythmogenic substrates. Late iodine enhancement computed tomography (LIE-CT) offers a promising alternative to cardiac MRI for preprocedural substrate visualization. This study evaluated procedural characteristics and outcomes of LIE-CT-supported VT ablation versus conventional mapping (CM) in NIDCM patients. Methods: NIDCM patients undergoing VT ablation between January 2022 and August 2024 were retrospectively analyzed. LIE-CT data were processed using inHEART software. Patients were matched 1:1 by propensity score based on baseline characteristics, electrical storm, and prior ablations. Results: A total of 46 patients (mean age 59 ± 16.4 years, 74% male) were included (23 LIE-CT, 23 CM). Procedure durations were comparable (231.5 ± 74.2 vs. 220.2 ± 70.2 min, p = 0.5), but mapping time (35.9 ± 15.3 vs. 54 ± 5 min, p < 0.001) and fluoroscopy time (14.7 ± 5.1 vs. 21.3 ± 10.6 min, p = 0.02) were significantly shorter with LIE-CT. Epicardial access was more frequent (52% vs. 26%, p < 0.001), and bipolar ablation for intramural scar was performed in 17% of LIE-CT cases. There were no significant differences in acute kidney injury or 30-day mortality. At a median follow-up of 367 days, VT-free survival was 57% with LIE-CT and 52% with CM (p = 0.8). Conclusions: LIE-CT-supported VT ablation and substrate visualization was safe, without additional risk of acute kidney injury, and enabled more efficient and targeted VT ablation. Prospective studies are warranted to assess its impact on long-term outcomes in NIDCM patients.
- Open Access
- 11 April 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 6 (4) , 675-682
Ultra-short-term heart rate variability using a photoplethysmography-based smartphone application: a TeleCheck-AF subanalysis
Aims: Autonomic nervous system activation plays an important role in the pathophysiology of atrial fibrillation (AF). It can be determined using heart rate variability (HRV). We aimed to evaluate the feasibility of using photoplethysmography (PPG) recordings for the assessment of the ultra-short-term HRV. Methods and results: TeleCheck-AF is a structured mobile health approach, comprising the on-demand use of a PPG-based smartphone application prior to a scheduled teleconsultation to ensure comprehensive remote AF management. Participants with at least one PPG recording in sinus rhythm were included to assess resting heart rate, root mean square of successive differences (RMSSD), patient compliance and data consistency. In total, 855 patients [39.4% women] with 13 465 recordings were included. Patient compliance was 95.2% (IQR 76.2–114.3%). Median heart rate per patient was 66.5 (IQR 60.0–74.0) b.p.m., median RMSSD per patient was 40 (IQR 33–50) ms and median recording consistency was ±5.2 (IQR 3.8–7.0) b.p.m. and ±14.8 (IQR 9.3–21.1) ms, respectively. RMSSD was lower in men than women, in patients with CHA2D2-VA-Score 0, with a history of AF, and following ablation of AF. Older age and lower body mass index were associated with higher RMSSD. Conclusion: The ultra-short-term HRV can be determined in 1-min PPG recordings with high user compliance and high inter-recording consistency within a structured mobile health AF management approach. The strategy used in this study may also be feasible for the management of other conditions in which the HRV plays a role for diagnostics and therapy.
- 11 April 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 6 (4) , 675-682
Open AccessUltra-short-term heart rate variability using a photoplethysmography-based smartphone application: a TeleCheck-AF subanalysis
Aims: Autonomic nervous system activation plays an important role in the pathophysiology of atrial fibrillation (AF). It can be determined using heart rate variability (HRV). We aimed to evaluate the feasibility of using photoplethysmography (PPG) recordings for the assessment of the ultra-short-term HRV. Methods and results: TeleCheck-AF is a structured mobile health approach, comprising the on-demand use of a PPG-based smartphone application prior to a scheduled teleconsultation to ensure comprehensive remote AF management. Participants with at least one PPG recording in sinus rhythm were included to assess resting heart rate, root mean square of successive differences (RMSSD), patient compliance and data consistency. In total, 855 patients [39.4% women] with 13 465 recordings were included. Patient compliance was 95.2% (IQR 76.2–114.3%). Median heart rate per patient was 66.5 (IQR 60.0–74.0) b.p.m., median RMSSD per patient was 40 (IQR 33–50) ms and median recording consistency was ±5.2 (IQR 3.8–7.0) b.p.m. and ±14.8 (IQR 9.3–21.1) ms, respectively. RMSSD was lower in men than women, in patients with CHA2D2-VA-Score 0, with a history of AF, and following ablation of AF. Older age and lower body mass index were associated with higher RMSSD. Conclusion: The ultra-short-term HRV can be determined in 1-min PPG recordings with high user compliance and high inter-recording consistency within a structured mobile health AF management approach. The strategy used in this study may also be feasible for the management of other conditions in which the HRV plays a role for diagnostics and therapy.